文章核心观点 Shuttle Pharmaceuticals与一名合格投资者达成证券购买协议，将发行股票募资425万美元用于潜在收购、营销等公司用途 [1] 融资情况 - 公司与合格投资者达成证券购买协议，总收益425万美元，扣除费用后净收益用于潜在收购、营销和其他一般公司用途 [1] - 公司将以每股3.60美元价格发行1180877股普通股或预融资认股权证，预计6月23日左右完成交易 [2] - WestPark Capital担任此次发行独家配售代理，更多细节将在公司提交给美国证券交易委员会的8 - K表格中披露 [3] 公司介绍 - 公司是专注改善放疗癌症患者治疗效果的专业制药公司，使命是开发疗法提高放疗效果并减少副作用 [6] 证券相关 - 上述证券未根据1933年证券法注册，仅向合格投资者发售，公司将向美国证券交易委员会提交注册声明 [4] 联系方式 - 公司首席执行官Chris Cooper邮箱为info@shuttlepharma.com，投资者联系邮箱为shph@lythampartners.com [9]

GAITHERSBURG, Md., June 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT) announces that the reverse stock split will become effective on June 16, 2025, at 12:01 a.m., Eastern Time. The Company’s common stock will continue to trade on The Nasdaq Capital Market (“Nasdaq”) under the existin ...

GAITHERSBURG, Md., June 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announces that its Board of Directors have approved a proposed reverse stock split of its common stock at a ratio of 25-for-1. The proposed action remains subject to approval by Nasdaq and, if approved, the Company ...

GAITHERSBURG, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of George Scorsis as the Chairman of the Board of Directors. Mr. Scorsis has served as director of the Company since February 2025. Mr. Scorsis has over 25 years of experience leadin ...

GAITHERSBURG, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update. Shuttle Pharma’s recent highlights: Phase 2 clinical trial of Ropidoxuridine for treatment of patients with glioblastoma highlights include: Patient enrollment nears milestone as n ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Commission File Number 001-41488 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter ...

GAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today that it has nearly achieved 50% enrollment in the initial randomized portion of its Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma, with treatment sites repo ...

Filing provisional patent application with the USPTO entitled "PSMA-Targeted PARP Inhibitor conjugates for Precision Cancer Therapy" key to advancement of Diagnostic and Therapeutic programs Dr. Alan Kozikowski, internationally acclaimed pioneer in the discovery of a critical PSMA targeting ligand for clinical applications is co-inventor Theranostic molecule designed to preferentially target prostate cancer cells to the effects of radiation and chemotherapeutic agents GAITHERSBURG, Md., April 10, 2025 (GLOB ...

GAITHERSBURG, Md., March 13, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today the closing of its previously announced underwritten public offering of 19,166,667 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at a public offering price of $0.30 pe ...

文章核心观点 - Shuttle Pharmaceuticals宣布公开发行普通股或预融资认股权证，预计募资约575万美元，用于产品临床试验、营销等用途 [1][2] 公司概况 - 公司由乔治城大学医学院教员于2012年创立，是一家专注改善放疗癌症患者预后的专业制药公司 [5] - 公司使命是开发疗法提高放疗有效性并减少副作用，目标是提高癌症治愈率、延长患者生存期和改善生活质量 [5] 发行情况 - 公司以每股0.30美元价格公开发行19,166,667股普通股或预融资认股权证，预计总收益约575万美元，发行预计于2025年3月13日完成 [1] - 发行以包销形式进行，WestPark Capital担任独家簿记管理人 [2] - 证券发行依据2025年3月7日生效的S - 1表格注册声明，将通过招股说明书进行，最终招股书将提交给美国证券交易委员会 [3] 资金用途 - 公司计划将发行所得净收益用于主导产品候选药物的二期临床试验、营销和广告服务以及营运资金和一般公司用途 [2] 联系方式 - 公司CEO为Anatoly Dritschilo，联系电话240 - 403 - 4212，邮箱info@shuttlepharma.com [8] - 投资者联系Lytham Partners的Robert Blum，电话602 - 889 - 9700，邮箱shph@lythampartners.com [8]